{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:45:34Z","timestamp":1768207534384,"version":"3.49.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chongqing Medical Leading Talent Project","award":["YXLJ202411"],"award-info":[{"award-number":["YXLJ202411"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Elderly patients with moderate-to-severe plaque psoriasis are vulnerable to adverse events (AEs), which raise safety concerns in their management. This\n                      <jats:italic>post-hoc<\/jats:italic>\n                      analysis aimed to evaluate the safety and efficacy of vunakizumab in elderly patients with moderate-to-severe plaque psoriasis, with an emphasis on safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data were extracted from a phase III trial (NCT04839016). A total of 70 elderly patients with moderate-to-severe plaque psoriasis were included and assigned to the vunakizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f49) and placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f21) groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During the induction period, the incidence of any AEs (63.3% vs. 76.2%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.291) and serious AEs (4.1% vs. 0.0%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f1.000) did not differ between the vunakizumab and placebo groups. During the entire treatment period, the incidence of any AEs (87.8% vs. 90.5%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f1.000) and serious AEs (10.2% vs. 4.8%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.661) remained unchanged between the vunakizumab and placebo groups. In the vunakizumab group, the most frequent AEs during the entire treatment period were elevated blood glucose (22.4%), hypertriglyceridemia (12.2%), elevated blood cholesterol (10.2%), eczema (10.2%), hyperuricemia (10.2%), and upper respiratory tract infection (10.2%). The rates of patients achieving psoriasis area and severity index (PASI) 75, 90, 100, and static physician\u2019s global assessment (sPGA) 0\/1 responses at week (W) 12 were higher in the vunakizumab group than in the placebo group (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). These trends were sustained for 52\u202fweeks. Patient-reported outcomes (PROs) at certain time points during 52\u202fweeks were better in the vunakizumab group than in the placebo group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vunakizumab is safe and effective in elderly patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1695266","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:45:29Z","timestamp":1768196729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profile of vunakizumab in elderly patients with moderate-to-severe plaque psoriasis: a post-hoc analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Tong","family":"Mu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanxiong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 Study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.3390\/biomedicines10112879","article-title":"Therapy of PsO in special subsets of patients","volume":"10","author":"Di Cesare","year":"2022","journal-title":"Biomedicine"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"113388","DOI":"10.1016\/j.intimp.2024.113388","article-title":"Current therapeutic overview and future perspectives regarding the treatment of psoriasis","volume":"143","author":"Ferrara","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/14712598.2022.2089020","article-title":"Treating psoriasis in the elderly: biologics and small molecules","volume":"22","author":"Megna","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub6","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"2023","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/14740338.2020.1728253","article-title":"Safety concerns with current treatments for psoriasis in the elderly","volume":"19","author":"Di Caprio","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s40265-024-02110-8","article-title":"Vunakizumab: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2024.09.031","article-title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"92","author":"Yan","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2106\/JBJS.O.00030","article-title":"Scoring the SF-36 in orthopaedics: a brief guide","volume":"97","author":"Laucis","year":"2015","journal-title":"J Bone Joint Surg Am"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","article-title":"A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis","volume":"87","author":"Zhang","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40266-014-0156-6","article-title":"Managing moderate-to-severe psoriasis in the elderly","volume":"31","author":"Balato","year":"2014","journal-title":"Drugs Aging"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1203475419897578","article-title":"Biologic treatment in elderly patients with psoriasis: a systematic review","volume":"24","author":"Sandhu","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e2024166","DOI":"10.5826\/dpc.1403a166","article-title":"Effectiveness of ixekizumab in elderly patients for the treatment of moderate-to-severe psoriasis: results from a multicenter, retrospective real-life study in the Lazio region","volume":"14","author":"Dattola","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.2147\/CCID.S487869","article-title":"Real-world experience of bimekizumab in an elderly patients cohort with plaque-type psoriasis: a 24-week retrospective study","volume":"17","author":"Fratton","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies","volume":"35","author":"K\u00f6rber","year":"2018","journal-title":"Drugs Aging"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/ced.14258","article-title":"Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period","volume":"45","author":"Megna","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/jdv.16063","article-title":"Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period","volume":"34","author":"Megna","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2452948","DOI":"10.1080\/09546634.2025.2452948","article-title":"Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study\u2014IL PSO (Italian Landscape Psoriasis)","volume":"36","author":"Orsini","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2393376","DOI":"10.1080\/09546634.2024.2393376","article-title":"Efficacy and safety of bimekizumab in elderly patients: real-world multicenter retrospective study\u2014IL PSO (Italian Landscape Psoriasis)","volume":"35","author":"Orsini","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"adv00316","DOI":"10.2340\/00015555-3678","article-title":"Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis","volume":"100","author":"Phan","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2147\/CCID.S400520","article-title":"Efficacy and safety of secukinumab in elderly patients with moderate to severe plaque-type psoriasis: post-hoc analysis of the SUPREME study","volume":"16","author":"Talamonti","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/14740338.2023.2173171","article-title":"Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients","volume":"22","author":"Megna","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jamadermatol.2022.1756","article-title":"Patient-relevant outcomes in psoriasis: a systematic review","volume":"158","author":"Hilhorst","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1365-2133.2011.10469.x","article-title":"Patient-reported outcomes in psoriasis research and practice","volume":"165","author":"Otuki","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2165\/00002512-200219110-00003","article-title":"Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options","volume":"19","author":"Yosipovitch","year":"2002","journal-title":"Drugs Aging"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jdv.17870","article-title":"Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation","volume":"36","author":"St\u00e4nder","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1695266\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:45:32Z","timestamp":1768196732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1695266\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":28,"alternative-id":["10.3389\/fmed.2025.1695266"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1695266","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1695266"}}